News

Novo Nordisk launches weight-loss drug Wegovy in India to compete with rival Lilly's Mounjaro
By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Danish drugmaker Novo Nordisk launched its blockbuster weight-loss ...
Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
STAT2h
Novo Nordisk, seen as lagging in obesity drug race, says it’s playing the long game
Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.
Novo Nordisk A/S (NVO): “How Could They Be So Far Behind?,” Wonders Jim Cramer
Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical giant that is a key player in the weight loss drug market. The firm’s ...
Novo Nordisk split puts Hims & Hers future in question
Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...
Novo Seeks Deals to Reverse Slide in Weight-Loss Market It Made
Novo Nordisk A/S is hunting for more early-stage deals to pad its pipeline of next-generation obesity drugs, as the drugmaker ...
Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...
Hims & Hers stock plunges after Novo Nordisk ends its brief partnership
The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...
Experimental drug helps patients lose nearly a quarter of body weight in early trials
Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...